Pfizer/Hospira's Biosimilar Pipeline: Substantial Overlap, Limited Divestiture So Far

One should not rule out Pfizer Inc. selling off more biosimilars than required under antitrust rules in its acquisition of Hospira Inc. All five biosimilars in Pfizer's clinical pipeline overlap with those in Hospira's, but even though only infliximab is required to be divested, the others could also be sold off to reach cost-saving targets.